Study of an anti-cancer drug alone or with immunotherapy
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer that cannot be cured, and there is no standard treatment that reliably helps (or you can’t take it).
- Your tumor can be measured on scans (doctors need measurable disease).
- For most parts, your cancer type must match the study list; for the CRC parts, it’s metastatic colon or rectal cancer after specific prior treatments.
- You must be able to provide stored tumor tissue and also two sets of tumor biopsies (before treatment and during treatment); in some sites, fresh tissue is required.
- You should be well enough for treatment (performance status 0–1), with life expectancy of at least 12 weeks and lab tests showing adequate organ function.
- You should not have certain heart rhythm problems on an ECG (QTc ≤ 480 milliseconds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.